1098-2299/asset/DDR_centre.gif?v=1&s=0de46fc8e2686c185b44eedd0a5a3895cd6d9afe)
Research Commentary
Developing medical countermeasures: from BioShield to BARDA
Article first published online: 12 JUN 2009
DOI: 10.1002/ddr.20299
© 2009 Wiley-Liss, Inc.
Issue
1098-2299/asset/cover.gif?v=1&s=c8b6d95b3bde54896854147d5045c8f3690d6eff "Drug Development Research")
Drug Development Research
Special Issue: Biodefense Countermeasure Development
Volume 70, Issue 4, pages 224–233, June 2009
Additional Information
How to Cite
Tucker, J. B. (2009), Developing medical countermeasures: from BioShield to BARDA. Drug Development Research, 70: 224–233. doi: 10.1002/ddr.20299
Publication History
- Issue published online: 12 JUN 2009
- Article first published online: 12 JUN 2009
- Abstract
- References
- Cited By
Keywords:
- medical countermeasures;
- biodefense;
- CBRN;
- BARDA;
- Project BioShield
Abstract
The U.S. Congress passed the Project BioShield Act in 2004 to create market incentives for the private sector to develop medical countermeasures (MCMs) against high-priority chemical, biological, radiological, and nuclear threats. Two years later, Congress patched recognized gaps in the BioShield legislation by adopting the Pandemic and All-Hazards Preparedness Act of 2006, which established the Biomedical Advanced Research and Development Authority (BARDA) within the Department of Health and Human Services (DHHS). BARDA provides financial and managerial support for companies developing MCMs. This article examines U.S. government efforts in the MCM field and prospects for the future. Drug Dev Res 70:224–233, 2009. © 2009 Wiley-Liss, Inc.